A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

NCT02193217 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

DRUG: MT-1303-Low
DRUG: MT-1303-High
DRUG: Fingolimod
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation